Showing results (111-120 of 243) with videos related to
Sort By:
Pageof 25
Respiratory Medicine and Research|April 23, 2023
Outcomes of extended resection for locally advanced thymic malignanciesJean Baptiste Menager, Olaf Mercier, Antonin Levy, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2026
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized CareClaudia Parisi, Andrea De Giglio, Marco Banini, et al.Clinical Lung Cancer|February 4, 2018
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Paul Baas, Fabrice Barlesi, et al.Investigational New Drugs|April 5, 2020
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancerNobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, et al.Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung CancerEmma Pailler, Vincent Faugeroux, Marianne Oulhen, et al.Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.JTO Clinical and Research Reports|May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLCBruce E Johnson, Christina S Baik, Julien Mazieres, et al.Pageof 25